Teacup

A German regional court has ruled that Google is directly liable for false claims in its AI-generated search overviews. In this case, Google's AI had wrongly linked two publishers to scams and shady business practices. The court treated the AI overviews as Google's own content and rejected Google's argument that users were responsible for fact-checking the results themselves.

Full Transcript at the link; 3-minute listen.

Quote:

By taking biopsies from long COVID patients before and after exercising, scientists in the Netherlands constructed a startling picture of widespread abnormalities in muscle tissue that may explain this severe reaction to physical activity.

Among the most striking findings were clear signs that the cellular power plants, the mitochondria, are compromised and the tissue starved for energy.

"We saw this immediately and it's very profound," says Braeden Charlton, one of the study's authors at Vrije University in Amsterdam.

The tissue samples from long COVID patients also revealed severe muscle damage, a disturbed immune response, and a buildup of microclots.

This article mentions that ME/CFS is a "similar complex condition" but that's DEEPLY underreporting the similarities. The phrase "post exertional malaise" (now researchers are trying to replace it but this article uses that phrase) was INVENTED for ME/CFS. It's the only known condition, before "long covid", that causes these kinds of symptoms after exertion!

It's good to know for sure that it's the same mechanisms at play when the inciting viral infection is Covid and not, for instance, Epstein-Barr or RSV, but half the time it doesn't seem like researchers are making comparisons at all, just reinventing the wheel and acting like "long covid" is a totally new phenomenon with no previous point of comparison. There are literally drugs in human trials to try to treat the mitochondrial dysfunction in ME, this dysfunction is well-established and fairly well understood and I feel insane when ppl report on long covid without mentioning that there is already a named and studied condition that accounts for this subset of symptoms!!

SOME researchers are drawing comparisons but they're largely ME researchers who everyone else is largely cignoring because of the widespread perception that ME is a fake disease for lazy women.

That same perception btw is why "graded exercise therapy" (GET), or exercise gradually increasing in intensity, cwas for years the go-to treatment despite MOUNTAINS of evidence that it makes ME patients sicker. Some end up permanently bedbound and unable to even eat or drink without a feeding tube/IV because the damage is so bad! The GET recommendation was finally changed only in the past few years in the US and the UK, and many doctors hate that they're not allowed to recommend it anymore, because they insist despite the evidence that ME/CFS is psychological and ME patients are just "deconditioned" and too lazy to do anything about it.

Now the same kind of "treatment" is being recommended for long covid patients despite evidence showing exercise is having the same kinds of cellular effects as it does in ME patients. "Taking PEM into account" sounds gentler but I'm deeply concerned about the reinvention of GET for patients who meet all the criteria for an illness that's been shown definitively to become permanently worse with GET. This mitochondrial damage is progressive in ME, and there's no reason to believe patients who meet all the criteria of ME after Covid won't experience the same progression if they force themselves past their energy envelope in such a systematic way.

The additional finding that T cells — part of the immune system's arsenal — had infiltrated the muscles of long COVID patients also caught Iwasaki's attention, possibly indicating "an autoimmune response within the muscle cells."

In 2021, Swarovski (the company that makes the very sparkly crystals you see in certain jewelry, on figure-skaters' twinkliest outfits, on red carpet dresses), decided they didn't want the grubby fingers of small-time jewelers, clothing designers and costumers and crafters on their shiny beads and rhinestones anymore. They decided to limit their sales to "luxury" and couture creators, not girls who sell stuff on Etsy. The tenor of their press release on the subject was snide and insulting. Resellers (like your favorite bead shop) would no longer be allowed to carry their product; the average Jane on the street would not be able to purchase them. You could only get them if you had an authorized business agreement that bound you to very strict brand behavior. And those of us who still had good stock of the crystals would no longer be "permitted" to use the brand's name in our listings for sale.

Every bead shop and craft supply place and many, many small clothing makers--wedding shops, prom and dancing dress suppliers, the sort of salt of the Earth mom and pop time machines of shops that are the backbone of the field--scrambled to find something that could replace them. The last of the stock dwindled quickly, all of us grabbing what we could get while there was any chance of it, and then it was gone and we no longer had any access.

I was Big Pissed about it at the time. It was just so goddamn stuck-up, when wholesalers and indie jewelers had made them so much money, when some people I knew--when *I!*--had been brand-loyal for decades. But with no recourse, everyone pivoted fairly quickly, most of us to Preciosa Crystals. Those are Czech, quite sparkly, and considerably less expensive than Swarovski. The faceting method they use is different, but not worse; any differences are hardly noticeable when you're seeing them as a hundred pinpoints of light.

Well, out of nowhere, Swarovski just dropped this: https://www.harmanbeads.com/swarovski-brand-policy-update

"Effective June 1, 2026, Swarovski updated the distribution and brand usage policies introduced in 2021. Businesses may now purchase Swarovski Crystals without signing a Brand Control Agreement, and Authorized Distribution Partners may once again sell Swarovski Crystals to resellers, including bead stores and online retailers. Businesses may also use the Swarovski brand name when following Swarovski’s Proper Use Guidelines. Designers, manufacturers, artists, brands, retailers, and resellers are now eligible to purchase Swarovski Crystals through authorized distribution channels."

They want us back. A lot of the companies who could have kept a brand relationship with them also have swapped to Preciosa, over the last half-decade, in solidarity with indie creators and out of a sour awareness that it could be them, next. And it doesn't hurt that Preciosa was able to expand their line quite a bit now that everyone who wanted sparkle had no choice but to go to them.

And I'm not seeing nearly anyone who intends to return. The feeling is, "Y'all told us to fuck off! Off we fucked! And now, that's what you can do, too!" I'm seeing a lot of "How many of us did you stab in the back?" comments from the people whose money they're hoping to attract.

The Amur Leopard and Clouded Leopard (which recently celebrated its 50th cub born at the zoo!)

The Sumatran Tiger

The Red Ruffed Lemur and Ring-Tailed Lemur

The Cotton-Top Tamarin and White-Cheeked Gibbon

The Colobus Monkey and De Brazza’s Monkey

And the Mexican Spider Monkey!

IT'S CALLED A BOQUILA TRIOFOLIOLATA AND IT'S FUCKING WITH MY BRAIN

IT APPARENTLY CAN MIMIC OTHER PLANTS AND AT FIRST I WAS LIKE "oh cool man it must take it's genetic code and copy it or feel the roots or something like that!! :3"

AND THEN I READ AN ARTICLE ON IT AND THESE FUCKING PARAGRAPHS HIT ME LIKE A BUS

LIKE READ THIS SHIT

Anis are bizarre, coal-black cuckoos with long floppy tails and unique, curiously tall, flattened bills. Groove-billed occurs in a variety of open and semi-open habitats in tropical lowlands and foothills, typically staying low in shrubs and grasses. Gregarious and not particularly graceful; usually seen crashing around awkwardly in small groups.

At the 1985 Labour party meet, the motion to support LGBT rights as a party was passed due to a block vote from mining unions.

"For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.

Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time."

Saved in our archive

Source